CoChat

MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation

Open access
Pellot Ortiz, Karolina I., Rechberger, Julian S., Nonnenbroich, Leo F., Daniels, David J., Sarkaria, Jann N. · 2023 · Biomedicines

The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.

Abstract

Inhibition of the interaction between MDM2 and p53 has emerged as a promising strategy for combating cancer, including the treatment of glioblastoma (GBM). Numerous MDM2 inhibitors have been developed and are currently undergoing rigorous testing for their potential in GBM therapy. Encouraging results from studies conducted in cell culture and animal models suggest that MDM2 inhibitors could effectively treat a specific subset of GBM patients with wild-type TP53 or functional p53. Combination therapy with clinically established treatment modalities such as radiation and chemotherapy offers the potential to achieve a more profound therapeutic response. Furthermore, an increasing array of other molecularly targeted therapies are being explored in combination with MDM2 inhibitors to increase the effects of individual treatments. While some MDM2 inhibitors have progressed to early phase clinical trials in GBM, their efficacy, alone and in combination, is yet to be confirmed. In this article, we present an overview of MDM2 inhibitors currently under preclinical and clinical investigation, with a specific focus on the drugs being assessed in ongoing clinical trials for GBM patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines11071879

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Summary of the p53–MDM2 regulatory loop and its intracellular implications. (1) MDM2 prevents p53 from regulating the transcription of MDM2 and other downstream target genes by binding to p53 directly. (2) Through interaction with various cytoplasmic proteins, MDM2 promotes SUMOylation and nuclear export of p53. (3) Most notably, MDM2 is an E3 ubiquitin ligase that targets p53 via ubiquitination for proteasomal degradation and thereby suppresses p53 transcriptional activity. All of these mechanisms work together to reduce p53 activity in the absence of cellular stress. Created with BioRender.com (accessed on 15 February 2023).
Figure 1 Summary of the p53–MDM2 regulatory loop and its intracellular implications. (1) MDM2 prevents p53 from regulating the transcription of MDM2 and other downstream target genes by binding to p53 directly. (2) Through interaction with various cytoplasmic proteins, MDM2 promotes SUMOylation and nuclear export of p53. (3) Most notably, MDM2 is an E3 ubiquitin ligase that targets p53 via ubiquitination for proteasomal degradation and thereby suppresses p53 transcriptional activity. All of these mechanisms work together to reduce p53 activity in the absence of cellular stress. Created with BioRender.com (accessed on 15 February 2023).CC BY · PubMed Central
Figure 2 Potential synergistic interactions between different therapeutic modalities and MDM2 inhibitors. Chemotherapy and radiation therapy (RT) remain the most promising and thoroughly researched combination partners for MDM2 inhibition. MDM2 and p53 activities are closely associated with the efficacy of chemotherapeutic drugs that work by damaging DNA, and inhibition of MDM2 renders tumor cells more susceptible to these types of pharmacotherapies. MDM2 inhibitors increase the effectiveness of RT by radiosensitizing tumor cells. Additionally, potential synergistic pathway inhibition with small-molecule-targeted therapies and other treatment modalities, such as immunotherapy, is conceivable and the subject of ongoing research (colored arrowheads signify examples of targeted molecules). Created with BioRender.com (accessed on 15 February 2023).
Figure 2 Potential synergistic interactions between different therapeutic modalities and MDM2 inhibitors. Chemotherapy and radiation therapy (RT) remain the most promising and thoroughly researched combination partners for MDM2 inhibition. MDM2 and p53 activities are closely associated with the efficacy of chemotherapeutic drugs that work by damaging DNA, and inhibition of MDM2 renders tumor cells more susceptible to these types of pharmacotherapies. MDM2 inhibitors increase the effectiveness of RT by radiosensitizing tumor cells. Additionally, potential synergistic pathway inhibition with small-molecule-targeted therapies and other treatment modalities, such as immunotherapy, is conceivable and the subject of ongoing research (colored arrowheads signify examples of targeted molecules). Created with BioRender.com (accessed on 15 February 2023).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 156 references

Cited by

See all 35

Metadata

Authors
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N.
Affiliations
  • Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
  • Mayo Clinic (US)
Corresponding author
Sarkaria, Jann N.
Venue
Biomedicines
Publisher
MDPI AG
Published
2023-07-02
Volume
11
Issue
7
Pages
1879
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4382940837
Cited by
30
References
157
Citations by year
2026: 4 · 2025: 13 · 2024: 12 · 2023: 1
FWCI
0.97
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Cancer Institute (U19CA264362)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
MDM2 inhibitors, glioblastoma, p53, p53-MDM2 interaction, wild-type p53, combination therapy, radiotherapy, chemotherapy, targeted therapy, clinical trials, preclinical drug development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation. https://app.cochat.ai/papers/10.3390/biomedicines11071879
The paper
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023). MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation. Biomedicines. https://doi.org/10.3390/biomedicines11071879

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.